Company Overview of Applied Genetic Technologies Corporation
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops gene therapy products for inherited orphan ophthalmology diseases in the United States. The company’s lead product candidates in the preclinical stage comprise treatments for X-linked retinoschisis, Congenital Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. It also has completed preclinical proof-of-concept studies, and Phase I and Phase II clinical trials of a treatment for alpha-1 antitrypsin deficiency, an inherited orphan lung disease. In addition, the company has proof-of-concept programs for other eye diseases, such as leber con...
11801 Research Drive
Alachua, FL 32615
Founded in 1999
Key Executives for Applied Genetic Technologies Corporation
Chief Executive Officer, President and Director
Total Annual Compensation: $313.9K
Chief Financial Officer and Principal Accounting Officer
Total Annual Compensation: $175.0K
Chief Medical Officer and Vice President
Total Annual Compensation: $336.2K
Senior Director of Process Development
Total Annual Compensation: $122.4K
Compensation as of Fiscal Year 2014.
Applied Genetic Technologies Corporation Key Developments
Applied Genetic Technologies Corporation Appoints Bruce A. Peacock to its Board of Directors
Mar 20 15
Applied Genetic Technologies Corporation announced that it has appointed Bruce A. Peacock to the company's Board of Directors. Mr. Peacock most recently served as Chief Business and Finance Officer for Ophthotech, where he was responsible for strategic planning, finance, manufacturing and business development. Previously, he was CEO and a member of the Board of Directors of The Little Clinic, LLC. During his tenure, he secured licensing arrangements with major national grocery retailers, achieved reimbursement from key payers and increased monthly patient traffic three-fold.
Applied Genetic Technologies Corporation Files Investigational New Drug Application for the Treatment of X-Linked Retinoschisis
Mar 10 15
Applied Genetic Technologies Corporation announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to conduct a Phase I/II clinical trial of the company's gene therapy product candidate for the treatment of X-linked retinoschisis (XLRS). Utilizing technology licensed from the University of Florida, AGTC's XLRS product candidate uses an AAV capsid with surface residues that have been specifically engineered for better penetration to the back of the eye. Pending the FDA's acceptance of the IND application, the Company plans to initiate a clinical study evaluating the safety and efficacy of AGTC's proprietary gene therapy for treating XLRS during the second quarter of 2015 and expects to have initial data during the second half of 2015.
Applied Genetic Technologies Corporation Presents at 3rd Annual Regen Med Investor Day, Mar-25-2015 02:10 PM
Feb 25 15
Applied Genetic Technologies Corporation Presents at 3rd Annual Regen Med Investor Day, Mar-25-2015 02:10 PM. Venue: Metropolitan Club, One East 60th Street, New York, NY 10022, United States. Speakers: Susan B. Washer, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 1, 2014